MMP9 Antibody, anti-human, REAfinity™
RECOMBINANT
Clone:
REA1556 | EP127
Type of antibody:
Recombinant antibodies, Primary antibodies
Isotype:
recombinant human IgG1
Applications:
MICS, IF, IHC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:

Related products for MMP9 Antibody, anti-human, REAfinity™

MICS (MACSima Imaging Cyclic Staining) applications
APC
FITC
PE
Fixation:
FFPE
Species tested:
human
Tissue used:
spleen
Recommended dilution:
1:50
Data source:
Miltenyi Biotec
Compatible applications:
IF, IHC
Conjugate:
APC
Used products:
130-141-935
Testing grade:
** Qualified
Description:
Immunofluorescence analysis of a formalin-fixed, paraffin embedded (FFPE) human spleen. Before staining, antigens were retrieved using heat-induced epitope retrieval (HIER) at pH 9. The section was stained using MMP9 Antibody, anti-human, APC (green) for 10 min at room temperature. Nuclei were visualized with Hoechst™ (blue). Scale bar: 30 µm.

Application imageView details view details

Application imageView details view details
Specifications for MMP9 Antibody, anti-human, REAfinity™
Overview

Clone REA1556 recognizes MMP9, also known as gelatinase B or 92 kDa type IV collagenase, which belongs to the family of matrix metalloproteinases that are responsible for the degradation of the extracellular matrix (ECM). The protein is secreted as an inactive pro-form and activated through proteolytic cleavage. MMP9 plays a central role in various physiological and pathological processes, such as local ECM proteolysis, leukocyte migration, protein regulation, and bone resorption. Furthermore, it is involved in embryonic development, tissue regeneration and reproduction, inflammatory processes, tumor progression and metastasis, as well as diseases such as arthritis and cardiovascular pathologies.

Detailed product information

Technical specifications

Clone
REA1556
Clonality
monoclonal
Isotype
recombinant human IgG1
Host
cell line
Type of antibody
Recombinant antibodies, Primary antibodies
Species reactivity
human
Antigen
MMP9

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for MMP9 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for MMP9 Antibody, anti-human, REAfinity™
Publications
  1. Takino, T. et al. (2003) Cleavage of metastasis suppressor gene product KiSS-1 protein/metastin by matrix metalloproteinases. Oncogene 22 (30): 4617-4626
  2. Lee, C. J. et al. (2024) The dysadherin/MMP9 axis modifies the extracellular matrix to accelerate colorectal cancer progression. Nat Commun 15 (1): 10422. doi
  3. Gong, Y. et al. (2008) Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J. Clin. Invest. 118 (9): 3012-3024